Loading...
•
Sep 30, 2024
Lantheus Q3 2024 Earnings Report
Reported an increase in worldwide revenue and adjusted EPS, driven by strong performance of PYLARIFY and DEFINITY, and expanded its Alzheimer's disease radiodiagnostics portfolio.
Key Takeaways
Lantheus reported a strong Q3 2024 with an 18.4% increase in worldwide revenue to $378.7 million. GAAP EPS was $1.79, while adjusted EPS was $1.70. The company is narrowing its full-year 2024 revenue and EPS guidance towards the higher end of previous estimates.
Worldwide revenue increased by 18.4% to $378.7 million compared to Q3 2023.
PYLARIFY sales increased by 20.6% to $259.8 million, driven by increasing volumes at existing accounts.
DEFINITY sales increased by 14.3% to $77.0 million, driven by market growth and competitor supply challenges.
GAAP fully diluted earnings per share decreased to $1.79, while adjusted fully diluted earnings per share increased by 15.6% to $1.70.
Lantheus
Lantheus
Lantheus Revenue by Segment
Revenue by Segment
PYLARIFY Revenue
CapyFin.comDEFINITY Revenue
CapyFin.comTechneLite Revenue
CapyFin.comOther Precision Diagnostics Revenue
CapyFin.comStrategic Partnerships and Other Revenue
CapyFin.com Forward Guidance
The company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income